# Abalos Therapeutics

Source: https://onco.cc/companies/abalos-therapeutics/  
OnCo record `abalos-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Abalos Therapeutics is testing a modified virus, given into a vein, that is designed to switch on the immune system inside tumours without destroying the infected cells. Its first medicine, ABX-001, is in an early trial for people with advanced solid tumours.

## Summary

Abalos Therapeutics GmbH, based in Düsseldorf, Germany, develops arenavirus-based immunotherapies built on lymphocytic choriomeningitis virus (LCMV), which it describes as a non-lytic viroimmunotherapy that replicates in cancer cells and antigen-presenting cells to trigger innate and adaptive immune responses inside the tumour (its AdaptInnate approach). The lead candidate ABX-001 entered a first-in-human, open-label, dose-escalation phase 1 study given as a single intravenous dose in about 18 patients with refractory or relapsed advanced solid tumours (EUCT 2024-512403-39-01); the company announced the first patient dosed on 23 October 2025. The ClinicalTrials.gov record, NCT07231458, also covers ABX-001 combined with pembrolizumab. Its first registered cancer trial, NCT07231458, was posted on ClinicalTrials.gov in November 2025. The company launched in October 2019 with a EUR 12 million Series A, and an extension led by Seventure Partners in October 2021 brought the Series A to EUR 43 million (USD 50 million); other investors named by the company include Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, NRW.BANK, Gründerfonds Ruhr, Coparion and Hx Bio Ventures. It also received EUR 1.2 million from Germany's KMU-innovativ programme.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Düsseldorf
- Type: biotech
- Website: https://abalos-tx.com/

## Notes

- Founding year not stated on the company website; its 2021 release says it launched in October 2019.
- The 2019 Series A release was listed on the company's news page but its text was not read; the EUR 12 million figure comes from the news page headline.
- ABX-001 is described by the company as non-lytic, so it is not linked to the oncolytic virus record.
- Company website and press releases read on 29 October 2026.

## Sources

- Official website: https://abalos-tx.com/
- First patient dosed with ABX-001, October 2025: https://abalos-tx.com/wp-content/uploads/2025/10/20251023_Abalos_PR_FPI_ABX-001_Final.pdf
- ClinicalTrials.gov: phase 1 trial of ABX-001 alone and with pembrolizumab (NCT07231458): https://clinicaltrials.gov/study/NCT07231458

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)

---
JSON: https://onco.cc/api/v1/entities/abalos-therapeutics.json